Teva Pharmaceutical Industries Limited (TLV:TEVA)
11,150
+130 (1.18%)
Aug 24, 2026, 12:54 PM IDT
Teva Pharmaceutical Industries Employees
As of December 31, 2025, Teva Pharmaceutical Industries had 32,842 total employees, including 31,173 full-time and 1,669 part-time employees. The number of employees decreased by 2,844 or -7.97% compared to the previous year.
Employees
32,842
Change
-2,844
Growth
-7.97%
Revenue / Employee
1.61M ILS
Profits / Employee
65.71K ILS
Market Cap
130.06B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 32,842 | -2,844 | -7.97% | 31,173 | 1,669 |
| Jun 30, 2025 | 37,000 | 0 | - | 37,000 | 0 |
| Mar 31, 2025 | 37,000 | 528 | 1.45% | 37,000 | 0 |
| Dec 31, 2024 | 35,686 | -786 | -2.16% | 33,892 | 1,794 |
| Sep 30, 2024 | 37,000 | 528 | 1.45% | 37,000 | 0 |
| Dec 31, 2023 | 36,472 | 1,347 | 3.83% | 35,001 | 1,471 |
| Dec 31, 2022 | 35,125 | -854 | -2.37% | 34,004 | 1,121 |
| Dec 31, 2021 | 35,979 | -2,393 | -6.24% | 34,713 | 1,266 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Amal Holdings A.D. | 28,991 |
| Danel (Adir Yeoshua) | 4,288 |
| Novolog (Pharm-Up 1966) | 916 |
| Kamada | 462 |
| Bait Bakfar | 244 |
| Ilex Medical | 181 |
| SofWave Medical | 151 |
| BrainsWay | 129 |
Teva Pharmaceutical Industries News
- 4 days ago - Aurinia settles patent litigation with Teva - TheFly
- 4 days ago - Aurinia Settles Patent Litigation with Teva - Business Wire
- 4 days ago - TEVA Stock Climbs as 50-Year-Long Tourette Syndrome Drug Breakthrough Moves Closer - TipRanks
- 4 days ago - Teva announces FDA acceptance of ecopipam NDA - TheFly
- 4 days ago - U.S. FDA Accepts Teva's New Drug Application (NDA) and Grants Priority Review for Ecopipam, a First-in-Class Investigational Therapy for Pediatric Patients with Tourette Syndrome - GlobeNewsWire
- 6 days ago - Teva price target raised to $42 from $40 at Barclays - TheFly
- 7 days ago - Teva price target raised to $42 from $40 at Barclays - TheFly
- 10 days ago - Humana agrees not to reference Teva's Israel ties at US drug trial - Reuters